Print this article

The most outstanding peptide achievement in the last two years

ANTONELLO PESSI

Chief
Scientific Officer, PeptiPharma

KEYWORDS: Diabesity; glucagon-like Peptide-1 (GLP-1), half-life extension, medical devices, short open reading frame-encoded polypeptide (SEP).

THE TRANSFORMATIVE EFFECT OF DIABESITY R&D

Research on Type 2 Diabetes (T2D) in conjunction with its main risk factor, obesity (“diabesity”), is having a transformative effect on the whole field of peptide therapeutics, and I have selected Semaglutide as a champion of this research.
Diabesity has reached epidemic proportions worldwide, and better management of the disease is still an unmet medical need. The competition among pharma companies for the huge associated pharmaceutical market ($41B in 2014) has favored a virtuous cycle of la